The introduction of sensor-augmented pumps with predictive low-glucose suspend and, especially, automated insulin delivery systems is a promising approach to further reduce the risk of hypoglycemia in T1D [4,5]. This evidence concerns the gene INS and type 1 diabetes mellitus.